Results 11 to 20 of about 39,848 (225)
BMJ, 2006 Last week an expert panel of the US Food and Drug Administration (FDA) recommended that the FDA should issue warnings to doctors and patients about drug eluting coronary stents. The safety of such stents is unclear except in low risk patients. Furthermore, patients with drug eluting stents should take antiplatelet therapy for at least one year after ...
Gershlick, AH, Richardson, G
+10 more sources
Canadian Medical Association Journal, 2007 In their recent systematic review, Suzanne Ligthart and associates compared analyses of the cost-effectiveness of drug-eluting stents.[1][1] They found that in most studies in which an incremental cost-effectiveness ratio greater than $50 000 per quality-adjusted life-year was calculated the ...
E Liana, Falcone, Navdeep, Tangri
+8 more sources
A novel glycyrrhizin acid-coated stent reduces neointimal formation in a rabbit iliac artery model
Frontiers in Pharmacology, 2023 Introduction: Most drug-eluting stents (DESs) inhibit intimal hyperplasia but impair re-endothelialization. This study aimed to evaluate in vivo strut coverage and neointimal growth in a new glycyrrhizin acid (GA)-eluting stent.Methods: New Zealand White
Shuai Teng +6 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Background and Objectives: The second-generation drug-eluting stents have been used to treat chronic total occlusion lesion. However, there is limited evidence of the clinical outcomes that whether the second-generation drug-eluting stents is superior to
Xuan Qiao +5 more
doaj +1 more source
Drug-eluting stent thrombosis [PDF]
Therapeutic Advances in Cardiovascular Disease, 2009 Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents (DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS).
Stähli, B E, Camici, G G, Tanner, F C
openaire +3 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Premature discontinuation of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention is related to higher short‐term risks of adverse outcomes. Whether these risks persist in the long‐term is uncertain. Methods and Results We
Scott Kinlay +11 more
doaj +1 more source
Progress in treatment by percutaneous coronary intervention: The stent of the future [PDF]
, 2013 First generation drug-eluting stents have considerably reduced in-stent restenosis and broadened the applications of percutaneous coronary interventions for the treatment of coronary artery disease.
Bourantas, C.V. (Christos) +11 more
core +3 more sources
The role of optical coherence tomography guidance in scaffold versus stent optimization
The Egyptian Heart Journal, 2020 Background Optical coherence tomography showed a great ability to identify adverse features during percutaneous coronary intervention with drug-eluting stents and resulted in better clinical outcomes.
Arif A. Al Nooryani +4 more
doaj +1 more source
Simulating Drug-Eluting Stents: Progress Made and the Way Forward [PDF]
, 2013 Drug-eluting stents have significantly improved the treatment of coronary artery disease. Compared with their bare metal predecessors, they offer reduced rates of restenosis and thus represent the current gold standard in percutaneous coronary ...
Kennedy, Simon +5 more
core +2 more sources
A mixed treatment comparison for short- and long-term outcomes of bare metal and drug eluting coronary stents [PDF]
, 2016 Background The increasing use of drug eluting stents in interventional cardiology calls for assessment of their efficacy and safety, both among drug eluting and bare-metal stents, in the context of rational decision making.
Dias, Sofia, Petrou, Panagiotis
core +2 more sources